First of its kind! Review of en-Chinese pharmaceutical antipsychotic drug chlornite flat tablets

Chlorniton tablets are antipsychotics and are mainly used to treat refractory schizophreniaCDE official website shows that, at present, a total of four domestic enterprises have declared the consistency of the species of supplementary applications, namely, Enhua Pharmaceuticals, Wanbond Pharmaceuticals, Changzhou Pharmaceuticals and Jiangsu Yunyang Group PharmaceuticalsAmong them, Enwar Pharmaceuticals is the first company to submit a supplementary applicationsource: CDE official websiteannouncement shows that, so far, Enhua Pharmaceuticals in the chlorine-nitrogen flat sheet consistency evaluation project has invested research and development costs of about 6.68 million yuanfocused on the central nervous drug market segment
Enhua Pharmaceuticals is positioned in the central nervous drug market, mainly engaged in the development, production and sales of central nervous system drugs, is a focus on the central nervous drug market segment of the enterprisemeters of internal network data show that in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public health institutions) terminal, the market size of psychosis drugs has exceeded 10 billion yuan since 2016, sales growth rate has been maintained at more than 10% per year, in 2018 to nearly 15 billion yuanFigure 1: China's public medical institutions terminal chemical drug psychostabilizing drug sales (unit: million yuan)source: Minet China's public medical institutions terminal competition pattern
from the competitive situation of enterprises, TOP3 enterprises are Hausen Pharmaceuticals, Hengrui Pharmaceuticals and Enhua Pharmaceuticals, three are the star pharmaceutical enterprises in Jiangsu Province, TOP3 enterprises total market share of more than 40%AstraZeneca and Xi'an Yangsen were fourth and fifth, with a market share of 6.69 percent and 5.60 percent in 2018, respectivelyFigure 2: China's public medical institutions end chemical drug psychosis drug TOP3 enterprise market share situationsource: Minet China's public medical institutions terminal competition pattern
Howson Pharmaceuticals and Hengrui Pharmaceuticals in China's public medical institutions terminal main force for anti-tumor drugs, psycho-stable medicine accounted for 21.32% of Hausen pharmaceutical industry, accounting for 11.05% of Hengrui Pharmaceuticalsin the sub-pattern of Enhua Pharmaceuticals, the proportion of psychosis drugs is close to 58%reference source:1, the company announcement2, minet: Jiangsu pharmaceutical companies three giants to dominate the ten billion market! Enhua half-year business first broke 2 billion, a bunch of new products to attack